Depletion of FAP+ CAFs, although has been reported to prolong survival in PDAC murine models91, administration of sibrotuzumab, a FAP-specific antibody, failed to improve survival for patients with metastatic colorectal cancer in a Phase II trial92, highlighting the importance of targeted therapy rather than widespread eradication of all CAFs. This evidence concerns the gene FAP and metastatic colorectal cancer.